ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM
Abstract Number: 2031
A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 2032
A Systematic Review of Treatment Strategies in VEXAS Syndrome
10:30AM-12:30PM
Abstract Number: 2025
Autonomic Nervous System Dysfunction Common Among Patients with Long COVID:Diagnosis and Treatment Implications
10:30AM-12:30PM
Abstract Number: 2037
Can Tofacitinib Be the Saviour in Treatment of Refractory IgG4-Related Disease : A Multicentre Experience from India
10:30AM-12:30PM
Abstract Number: 2039
Canakinumab Treatment in Patients with Familial Mediterranean Fever: A Tertiary Center Experience
10:30AM-12:30PM
Abstract Number: 2026
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
10:30AM-12:30PM
Abstract Number: 2036
CCN6 Gene Mutation Induces Mitochondrial Dysfunction: The Cause of Progressive Pseudo-rheumatoid Dysplasia
10:30AM-12:30PM
Abstract Number: 2050
Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies
10:30AM-12:30PM
Abstract Number: 2027
Clinical Features and Treatment of Retroperitoneal Fibrosis in a Referral Hospital and Literature Review
10:30AM-12:30PM
Abstract Number: 2057
Clinical Features of Autoimmune Uveitis and Associated Factors with Reactivation Subtype Presentation from a Peruvian Multidisciplinary Reference Center
10:30AM-12:30PM
Abstract Number: 2051
Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience
10:30AM-12:30PM
Abstract Number: 2044
Clinical Practice Patterns, Rilonacept Appropriate Use for Recurrent Pericarditis
10:30AM-12:30PM
Abstract Number: 2055
Demographic and Ocular Characteristics of Scleritis Patients with Systemic Rheumatologic Disease in the IRIS® Registry (Intelligent Research in Sight)
10:30AM-12:30PM
Abstract Number: 2045
Descriptive Study on the Use of Serum Levels of Immunoglobulin G4, Immunoglobulin E and Eosinophil Count as Serum Biomarkers Across Four Clinical Phenotypes of IgG4-Related Disease
10:30AM-12:30PM
Abstract Number: 2056
Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
10:30AM-12:30PM
Abstract Number: 2046
Duration of Disease and Long-term Outcomes in Patients with Difficult-to-treat Recurrent Pericarditis: A Chronic Condition Treated with NSAIDs, Colchicine, Corticosteroids, and Anti-IL-1 Agents
10:30AM-12:30PM
Abstract Number: 2040
Effective Management of Idiopathic Recurrent Pericarditis with Anakinra in Clinical Practice
10:30AM-12:30PM
Abstract Number: 2034
Effectiveness and Tolerability of Tocilizumab in Systemic Autoimmune Rheumatic Disease Associated Intertistial Lung Disease
10:30AM-12:30PM
Abstract Number: 2043
Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study
10:30AM-12:30PM
Abstract Number: 2049
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
10:30AM-12:30PM
Abstract Number: 2041
Global Prevalence and Clinical Outcomes of Cogan Syndrome
10:30AM-12:30PM
Abstract Number: 2029
Iron Deficiency in Familial Mediterranean Fever: A Study on 211 Adult Patients from the JIR Cohort
10:30AM-12:30PM
Abstract Number: 2038
Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection
10:30AM-12:30PM
Abstract Number: 2035
Older Age and Higher Erythrocyte Sedimentation Rate Are Associated with Increased Disease Burden at Diagnosis in a Cohort of IgG4-Related Disease Patients
10:30AM-12:30PM
Abstract Number: 2042
Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center
10:30AM-12:30PM
Abstract Number: 2054
Phenotypical Differences in VEXAS Syndrome, Where Are We a Year Later? Results from a National Cohort Focused on Rheumatological Patients
10:30AM-12:30PM
Abstract Number: 2053
Presence of ANA to Development of Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 2048
Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study
10:30AM-12:30PM
Abstract Number: 2052
Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center
10:30AM-12:30PM
Abstract Number: 2047
Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease
10:30AM-12:30PM
Abstract Number: 2033
Scleritis and the Rheumatologist. Does the Type of Scleritis Help to Distinguish an Infectious Cause from an Immune Cause? Among the Immune Causes, Does It Help Differentiate Between Systemic Causes and Those Limited to the Eye?
10:30AM-12:30PM
Abstract Number: 2030
The Development of the EULAR Score for the Definition of Disease Activity in Adult-onset Still’s Disease; The “DAVID” Project
10:30AM-12:30PM
Abstract Number: 2028
Therapeutic Insights in VEXAS Syndrome from a Multicenter Study in Spain: Moving Towards Amore Specific and Effective Treatment

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology